MENARINI is a fully integrated privately owned pharma company with a long and successful heritage in strategic partnering across the globe. We have a profound know-how stemming from our strong R&D capabilities in key therapeutic areas, coupled with our excellence in commercial execution and our powerful direct presence on a global basis.
Oncology
Developing effective cancer treatments remains one of the biggest priorities in healthcare today, and we are committed to making a difference to the lives of patients with difficult-to-treat cancers.
Constant advancement in our understanding of the molecular mechanisms underpinning the emergence, growth and spreading of tumors is expanding the potential for targeted approaches to treat cancer. This progress is based on evidence that the molecular and genetic profiles of tumors are as different as the patients in whom they occur, and better outcomes can be achieved by treating patients based on the specific characteristics of a tumor.
Menarini’s ability to identify and develop cancer treatments that specifically target distinctive molecular or genetic profiles of tumors can provide greater efficacy, improved safety, and hence better outcomes for patients. At the same time, dissecting a tumor’s genetic heterogeneity is essential to understanding tumor clonal evolution, providing an opportunity to develop new precision medicine strategies to address the emergence of resistance to current treatments.
That is why our work in oncology is focused both on therapeutics and diagnostics. We invest in the development of precision medicine through our pipeline of investigational drugs, while developing innovative technologies for the detection and analysis of circulating tumor cells, that enable their molecular characterization.
Through a precision medicine approach, we work with patients that carry specific molecular markers contributing to tumor growth and the spreading of tumor cells. These patients are expected to receive the most tangible benefit from treatment by achieving improved therapeutic results with less side effects.
As part of our strong commitment to oncology, in June 2020 Menarini acquired Stemline Therapeutics, a New-York based commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, strengthening Menarini’s oncology pipeline with the addition of both commercial and clinical-stage assets.
Our pipeline and products
Find out more about our pipeline of potential new treatments
Our technologies for rare cells analysis
Find out more about our technologies and the work of Menarini Silicon Biosystems
OUR PARTNERS IN ONCOLOGY
Partnerships are an integral part of our R&D strategy. By leveraging our expertise and resources, we work with our partners to transform their discoveries into innovative health care solutions that can make the difference for cancer patients.
BUILDING EXCELLENCE TOGETHER
Learn more about our approach to partnerships.
Expanded access programs
The Menarini Group is committed to developing new therapies to address the unmet medical needs of patients suffering from rare and seriously debilitating diseases.
We recognize that some patients who wish to access our medicines will not be eligible for clinical trials and may have no other viable treatment options available to them.
In these situations, we will consider providing pre-approval access to our investigational medicines, outside of the clinical trial setting, when certain conditions are met.
Our projects in onco-hematology
The HARMONY Alliance is a European Network of excellence that captures, integrates, analyzes and harmonizes Big Data from high-quality multidisciplinary sources for the purpose of acquiring valuable knowledge across the spectrum of blood cancers i.e. hematologic malignancies (HMs).
